11.04.2024 22:30:06 - dpa-AFX: GNW-Adhoc: Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
Mont-Saint-Guibert, Belgium - April 11, 2024, 10:30pm CET / 4:30pm ET - Nyxoah
SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical
technology company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the
appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer.
Dr. Boon joins Nyxoah from the Thomas Jefferson University, where he will
continue part time as a professor and Vice Chairman, Education. He is dual
board-certified in otolaryngology - head and neck surgery, as well as sleep
medicine. Dr. Boon is one of two sleep surgeons with Jefferson Health to pioneer
the use of hypoglossal nerve stimulation therapy (HGNS) and is internationally
recognized as one of the most experienced surgeons performing HGNS procedures.
He has lectured worldwide on obstructive sleep apnea, has numerous publications
and is co-editor of the first book on HGNS.
"As an academic physician who has dedicated my professional career to the care
of patients with sleep disordered breathing, I was privileged to participate in
the DREAM U.S. pivotal trial. I was initially impressed by the results I saw in
my patients and then equally impressed by the data that were recently reported.
As such, I am honored to have been offered a position to join Nyxoah at such an
exciting time. Bilateral hypoglossal nerve stimulation with Genio has tremendous
potential and I am thrilled to work with their talented team to make a
meaningful impact on the lives of patients with obstructive sleep apnea,"
commented Dr. Boon.
"I could not be more excited to have Dr. Boon join Nyxoah. He is one of the
pioneers in hypoglossal nerve stimulation and his decision to become Nyxoah's
Chief Medical Officer reflects Genio's ability to improve the lives of OSA
patients," commented Olivier Taelman, Chief Executive Officer. "Dr. Boon will
play a critical role as we prepare to enter the U.S. market and achieve our
mission of making sleep simple again."
About Nyxoah
Nyxoah is a medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive Sleep Apnea
(OSA). Nyxoah's lead solution is the Genio® system, a patient-centered, leadless
and battery-free hypoglossal neurostimulation therapy for OSA, the world's most
common sleep disordered breathing condition that is associated with increased
mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision
that OSA patients should enjoy restful nights and feel enabled to live their
life to its fullest.
For more information, please visit http://www.nyxoah.com/.
Caution - CE marked since 2019. Investigational device in the United States.
Limited by U.S. federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-
looking, which reflect the Company's or, as appropriate, the Company directors'
or managements' current expectations regarding the Genio® system; planned and
ongoing clinical studies of the Genio® system; the potential advantages of the
Genio® system; Nyxoah's goals with respect to the development, regulatory
pathway and potential use of the Genio® system; the utility of clinical data in
potentially obtaining FDA approval of the Genio® system; and the Company's
results of operations, financial condition, liquidity, performance, prospects,
growth and strategies. By their nature, forward-looking statements involve a
number of risks, uncertainties, assumptions and other factors that could cause
actual results or events to differ materially from those expressed or implied by
the forward-looking statements. These risks, uncertainties, assumptions and
factors could adversely affect the outcome and financial effects of the plans
and events described herein. Additionally, these risks and uncertainties
include, but are not limited to, the risks and uncertainties set forth in the
"Risk Factors" section of the Company's Annual Report on Form 20-F for the year
ended December 31, 2023, filed with the Securities and Exchange Commission
("SEC") on March 20, 2024, and subsequent reports that the Company files with
the SEC. A multitude of factors including, but not limited to, changes in
demand, competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development. Forward
looking statements contained in this press release regarding past trends or
activities are not guarantees of future performance and should not be taken as a
representation that such trends or activities will continue in the future. In
addition, even if actual results or developments are consistent with the
forward-looking statements contained in this press release, those results or
developments may not be indicative of results or developments in future periods.
No representations and warranties are made as to the accuracy or fairness of
such forward-looking statements. As a result, the Company expressly disclaims
any obligation or undertaking to release any updates or revisions to any
forward-looking statements in this press release as a result of any change in
expectations or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based, except if specifically
required to do so by law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such person's
officers or employees guarantees that the assumptions underlying such forward-
looking statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking statements
contained in this press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on forward-looking statements,
which speak only as of the date of this press release.
Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com (mailto:david.demartino@nyxoah.com)
+1 310 310 1313
Â